Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/3 Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer

Next Previous
Trial Profile

A Phase 1b/3 Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Sintilimab (Primary)
  • Indications Adenocarcinoma; Colon cancer; Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms Neoshot
  • Sponsors Innovent Biologics

Most Recent Events

  • 23 Feb 2025 According to an Innovent Biologics media release, company announces that the New Drug Application for ipilimumab injection has been accepted by the Center for Drug Evaluation of Chinas National Medical Products Administration (NMPA) and granted Priority Review designation in combination with sintilimab as neoadjuvant treatment for resectable microsatellite instability-high or mismatch repair deficient colon cancer based on results from this trial
  • 04 Jun 2024 Results (As of February 4, 2024, n=101) assessing safety and efficacy of IBI310 plus sintilimab as neoadjuvant treatment in patients with microsatellite instability-high /mismatch repair-deficient colorectal cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology
  • 27 Mar 2024 Results presented in an Innovent Biologics Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top